BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, highlights the presentation of data derived from the use of the Company’s proprietary platform bfLEAP® with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms. The data will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on Jan. 9 at poster session B.